NCT/Study#

NCT04164082 /

A031803

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

DISEASE GROUP:
Genito-Urinary
current phase:
Phase II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: